BeiGene (BGNE) Stock Price, News & Analysis

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

10 brokerages have issued 12-month price objectives for BeiGene's stock. Their BGNE share price targets range from $161.00 to $345.00. On average, they anticipate the company's stock price to reach $251.93 in the next year. This suggests a possible upside of 65.0% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $180.36 at the beginning of the year. Since then, BGNE shares have decreased by 15.3% and is now trading at $152.71.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our BGNE earnings forecast.

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($2.41) earnings per share for the quarter, beating the consensus estimate of ($3.07) by $0.66. The company had revenue of $751.70 million for the quarter, compared to analysts' expectations of $670.09 million. BeiGene had a negative trailing twelve-month return on equity of 21.70% and a negative net margin of 28.39%. The business's revenue for the quarter was up 67.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($3.34) earnings per share.

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Tema Oncology ETF (CANC), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB) and BlackRock Future Health ETF (BMED).

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

BeiGene (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

BeiGene's stock is owned by a number of retail and institutional investors. Top institutional investors include Capital International Investors (7.38%), Baillie Gifford & Co. (3.90%), Price T Rowe Associates Inc. MD (2.12%), Capital International Inc. CA (0.90%), Artal Group S.A. (0.42%) and Capital Group Private Client Services Inc. (0.22%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.